Rivastigmine (Exelon)
Rivastigmine Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Mild-to-moderate Alzheimer’s disease dementia | Adults | Monotherapy | FDA Approved |
| Mild, moderate, and severe Alzheimer’s disease dementia | Adults (transdermal patch only) | Monotherapy | FDA Approved |
| Mild-to-moderate Parkinson’s disease dementia | Adults | Monotherapy | FDA Approved |
Rivastigmine is one of the cornerstone pharmacotherapies for dementia associated with both Alzheimer’s disease (AD) and Parkinson’s disease (PD). The oral formulation is approved for mild-to-moderate disease severity, while the transdermal patch received expanded approval in 2013 to cover all stages of AD including severe dementia. Its dual inhibition of both acetylcholinesterase and butyrylcholinesterase distinguishes it pharmacologically from donepezil and galantamine, which are selective for AChE. This broader mechanism may offer particular benefit in patients with prominent neuropsychiatric symptoms such as hallucinations and behavioural disturbance.
Dementia with Lewy bodies (DLB): Rivastigmine has been studied in open-label trials for cognitive and behavioural symptoms of DLB, given the overlap between DLB and PDD neuropathology. Evidence quality: Moderate.
Postoperative delirium prevention: Small RCTs suggest the rivastigmine patch may reduce delirium incidence in older surgical patients with pre-existing cognitive impairment. Evidence quality: Low.
Gait instability in Parkinson’s disease (without dementia): The ReSPonD trial (Phase 2) demonstrated reductions in fall frequency with oral rivastigmine in PD patients without dementia. Evidence quality: Moderate.
Rivastigmine Dosing
Oral Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Alzheimer’s dementia — new diagnosis, oral | 1.5 mg BID | 3–6 mg BID | 6 mg BID (12 mg/day) | Titrate by 1.5 mg/dose every 2 weeks as tolerated Give with food; higher doses correlate with greater benefit (FDA PI) |
| Parkinson’s disease dementia — oral | 1.5 mg BID | 3–6 mg BID | 6 mg BID (12 mg/day) | Slower titration: increase by 1.5 mg/dose every 4 weeks Longer titration interval reduces GI side effects |
| Alzheimer’s dementia — transdermal patch initiation | 4.6 mg/24 h patch | 9.5 mg/24 h patch | 13.3 mg/24 h patch | Increase after minimum 4 weeks at each dose 9.5 mg/24 h is the minimum effective patch dose |
| Severe Alzheimer’s dementia — transdermal patch | 4.6 mg/24 h patch | 13.3 mg/24 h patch | 13.3 mg/24 h patch | Target the highest tolerated dose ACTION trial supported 13.3 mg/24 h in severe AD |
| Parkinson’s disease dementia — transdermal patch | 4.6 mg/24 h patch | 9.5 mg/24 h patch | 13.3 mg/24 h patch | Increase after minimum 4 weeks per step Patch associated with fewer GI effects than capsules in PDD |
| Switching from oral to transdermal | <6 mg/day oral → 4.6 mg/24 h patch; 6–12 mg/day oral → 9.5 mg/24 h patch | 13.3 mg/24 h patch | Apply first patch the day after last oral dose Do not use patch and oral simultaneously | |
| Treatment interruption — restart | 1.5 mg BID (oral) or 4.6 mg/24 h (patch) | Re-titrate to target | Same as original target | If interrupted >3 days, restart at lowest dose and re-titrate Abrupt re-initiation at prior dose risks severe vomiting |
Special Population Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Low body weight (<50 kg) | 1.5 mg BID | Individually titrated | Tolerated dose | Drug exposure approximately doubles at 35 kg vs 65 kg; monitor closely for GI toxicity |
| Hepatic impairment (Child-Pugh A/B) | 1.5 mg BID or 4.6 mg/24 h patch | Lower doses only | 4.6 mg/24 h patch (per StatPearls) | Oral clearance 60–65% lower in hepatic impairment; severe (Child-Pugh C) not studied |
| Renal impairment (moderate–severe) | 1.5 mg BID or 4.6 mg/24 h patch | Individually titrated | Tolerated dose | May tolerate lower doses only; titrate based on tolerability |
The 9.5 mg/24 h patch delivers comparable systemic exposure to the maximum oral dose (12 mg/day capsules) but with a smoother pharmacokinetic profile. In the IDEAL trial, the patch produced approximately two-thirds fewer reports of nausea and vomiting compared with oral capsules at equivalent efficacy, making it the preferred formulation for patients with poor GI tolerability.
Pharmacology
Mechanism of Action
Rivastigmine is a carbamate-type, pseudo-irreversible inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). It forms a covalent carbamylated complex with the enzyme’s active-site serine residue, producing sustained inhibition that outlasts the drug’s short plasma half-life. The pharmacodynamic duration of effect is approximately 8 to 10 hours, even though plasma levels decline within 1–2 hours. This “slow-off” binding characteristic drives a disconnect between the brief pharmacokinetic half-life and the longer duration of clinical activity. Rivastigmine demonstrates regional selectivity in the CNS, preferentially inhibiting the G1 isoform of AChE concentrated in the hippocampus and cortex — areas critically involved in memory and executive function. Its additional inhibition of BuChE, which is up-regulated in AD brain tissue as AChE declines, may provide a pharmacological advantage in patients with more advanced or rapidly progressing disease, particularly those with prominent neuropsychiatric features such as hallucinations.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid and nearly complete (>96%); Tmax ~1 h oral; bioavailability ~36% at 3 mg (extensive first-pass metabolism); food delays Tmax by 90 min, reduces Cmax ~30%, but increases AUC ~30% | Administer with food to improve tolerability and enhance overall exposure, though peak levels are lower |
| Distribution | Vd 1.8–2.7 L/kg; ~40% plasma protein binding; crosses BBB readily; CSF Tmax 1.4–2.6 h; CSF/plasma AUC ratio ~40% | Extensive CNS penetration supports central pharmacological effect; low protein binding minimises displacement interactions |
| Metabolism | Primarily hydrolysed by target cholinesterases to decarbamylated metabolite (NAP226-90); minimal CYP450 involvement; nonlinear PK at doses >3 mg BID (3-fold AUC increase when doubling from 3 to 6 mg BID) | CYP-independent metabolism makes rivastigmine one of the lowest interaction-risk cholinesterase inhibitors; saturable first-pass explains nonlinear kinetics at higher doses |
| Elimination | t½ ~1.5 h; >90% renally excreted as metabolites within 24 h; <1% in faeces | Short half-life limits accumulation and allows rapid washout; dialysis is not effective for overdose due to rapid endogenous clearance |
Side Effects
Adverse effects are driven by peripheral and central cholinergic stimulation and are strongly dose-related. Gastrointestinal effects predominate during titration and often attenuate at stable doses. Incidence data below are from controlled clinical trials of oral rivastigmine 6–12 mg/day in Alzheimer’s disease (FDA PI, n = 1,189 rivastigmine vs n = 868 placebo) unless noted otherwise.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 47% (vs 12% placebo) | Most common reason for discontinuation; higher during titration (43%) than maintenance (17%); take with food |
| Vomiting | 31% (vs 6% placebo) | Higher during titration (24%) vs maintenance (14%); severe in 2% of patients; more frequent in women |
| Dizziness | 21% (vs 11% placebo) | Central and cholinergic origin; advise caution with driving and machinery |
| Diarrhea | 19% (vs 11% placebo) | Cholinergic-mediated increase in GI motility; usually self-limiting |
| Anorexia | 17% (vs 3% placebo) | Monitor weight regularly; 26% of women on high doses experienced ≥7% weight loss |
| Headache | 17% (vs 12% placebo) | Usually mild and transient; no specific management required |
| Abdominal pain | 13% (vs 6% placebo) | Related to increased gastric acid secretion; consider antacids if persistent |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Fatigue | 9% (vs 5% placebo) | May compound cognitive slowing in dementia patients; assess functional impact |
| Insomnia | 9% (vs 7% placebo) | Consider timing of evening dose; avoid late-night administration |
| Dyspepsia | 9% (vs 4% placebo) | Consistent with increased gastric acid; PPI or H2-blocker if needed |
| Confusion | 8% (vs 7% placebo) | Difficult to distinguish from disease progression; evaluate if new-onset |
| Urinary tract infection | 7% (vs 6% placebo) | Likely related to underlying population risk rather than drug mechanism |
| Asthenia | 6% (vs 2% placebo) | Dose-related; may improve with dose adjustment |
| Depression | 6% (vs 4% placebo) | Screen for mood changes at follow-up visits; may overlap with dementia-associated apathy |
| Malaise | 5% (vs 2% placebo) | Non-specific; may be related to GI intolerance or anorexia |
| Somnolence | 5% (vs 3% placebo) | Warn regarding driving impairment; particularly relevant in PDD population |
| Anxiety | 5% (vs 3% placebo) | Cholinergic arousal may contribute; usually mild |
| Tremor | 4% (vs 1% placebo) | Especially relevant in PDD (10.2% in EXPRESS trial); not reflected in UPDRS motor worsening |
| Increased sweating | 4% (vs 1% placebo) | Cholinergic stimulation of sweat glands; typically mild |
| Weight loss | 3% (vs <1% placebo) | 18–26% of patients on high dose experienced ≥7% loss of baseline weight |
| Syncope | 3% (vs 2% placebo) | Vagotonic effect on heart rate; assess in patients with cardiac conduction disease |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe vomiting with dehydration | Uncommon | Titration phase or after dose re-initiation | Hold drug, IV fluid replacement, restart at lowest dose; esophageal rupture reported post-marketing after inappropriate re-initiation |
| Bradycardia / vagotonic cardiac effects | Rare | Any time during therapy | ECG monitoring in patients with sick sinus syndrome or conduction disorders; discontinue if symptomatic bradycardia |
| Gastrointestinal haemorrhage / peptic ulcer | Rare | Any time; increased risk with NSAIDs | Monitor for occult bleeding; discontinue if active bleed; avoid concurrent NSAIDs when possible |
| Seizures | Rare | Any time | Differentiate from disease-related seizure activity; hold rivastigmine and evaluate |
| Disseminated allergic dermatitis | Very rare (post-marketing) | Days to weeks after patch initiation | Discontinue all rivastigmine formulations immediately; switch to oral form only after negative allergy testing |
| Cholinergic crisis (overdose) | Very rare | Within hours of ingestion | Atropine sulphate as antidote; supportive care; no role for dialysis given short half-life |
| Medication errors (patch dosing) | Uncommon (post-marketing) | Any time; especially with caregiver-applied patches | Ensure old patch is removed before applying new one; multiple patch application has caused hospitalisation and death |
| Reason for Discontinuation | Incidence (Rivastigmine) | Context |
|---|---|---|
| Nausea | 8% | vs <1% placebo; predominantly during titration phase |
| Vomiting | 5% | vs <1% placebo; more common in women |
| Anorexia | 3% | vs 0% placebo; often accompanied by clinically significant weight loss |
| Dizziness | 2% | vs <1% placebo; central cholinergic effect |
Always administer rivastigmine with food. Use the slowest tolerated titration schedule. If nausea or vomiting becomes intolerable, hold for several doses and restart at the same or next lower dose. If treatment is interrupted for more than 3 days, restart from the lowest dose (1.5 mg BID oral or 4.6 mg/24 h patch) to prevent severe vomiting. Consider switching to the transdermal patch, which produces significantly fewer GI adverse effects at equivalent therapeutic exposure.
Drug Interactions
Rivastigmine has an unusually favourable interaction profile because it is metabolised by its own target enzymes (cholinesterases) rather than hepatic cytochrome P450 isoenzymes. Population pharmacokinetic analysis of 625 patients confirmed no clinically significant interactions with commonly prescribed medications including antihypertensives, beta-blockers, calcium channel blockers, NSAIDs, estrogens, and antihistamines. No pharmacokinetic interaction was observed with digoxin, warfarin, diazepam, or fluoxetine in dedicated healthy-volunteer studies. However, pharmacodynamic interactions at the cholinergic synapse remain clinically important.
Monitoring
-
Cognitive function
Baseline, then every 3–6 months
Routine Use standardised tools (MMSE, MoCA) to assess whether therapy is providing benefit. If no stabilisation or improvement after 3–6 months at target dose, reassess continuation of treatment. -
Body weight
Each visit during titration, then every 3 months
Routine Significant weight loss (≥7% baseline) occurred in 18–26% of patients on high oral doses. Assess nutritional status; consider dietitian referral if weight loss is progressive. -
GI tolerability
Each visit during titration
Routine Ask about nausea, vomiting, diarrhea, and appetite at each dose escalation. Hold and re-titrate if symptoms are intolerable. Consider switching to transdermal patch for persistent GI effects. -
Heart rate & ECG
Baseline; then as clinically indicated
Trigger-based Vagotonic effects may cause bradycardia, especially in patients with pre-existing sick sinus syndrome, supraventricular conduction defects, or concurrent use of beta-blockers. Obtain ECG if syncope or dizziness is reported. -
Motor function (PDD)
Every 3 months in PDD patients
Routine Worsening of parkinsonian symptoms (particularly tremor) has been observed. Monitor with UPDRS if available. Although motor score deterioration was not significant in the EXPRESS trial, individual patients may be affected. -
Patch application sites
At each patch change; review at clinic visits
Routine Inspect for application-site erythema, oedema, or vesicles. Rotate sites every 24 h; do not reuse the same site within 14 days. Discontinue if reaction spreads beyond patch area or does not resolve within 48 h of removal. -
Hepatic function
Baseline in at-risk patients
Trigger-based Oral clearance is 60–65% lower in hepatically impaired patients. Baseline liver function tests in patients with known liver disease; adjust dose accordingly.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to rivastigmine, other carbamate derivatives, or any component of the formulation
- Previous allergic contact dermatitis to the rivastigmine transdermal patch, in the absence of negative allergy testing confirming it is safe to retry
Relative Contraindications (Specialist Input Recommended)
- Sick sinus syndrome or supraventricular conduction disorders: Vagotonic effects may worsen bradycardia; cardiology input recommended before initiating
- Active peptic ulcer disease or GI bleeding: Cholinesterase inhibition increases gastric acid secretion; gastroenterology clearance advisable
- Severe hepatic impairment (Child-Pugh C): No dosing data available; significantly reduced clearance expected
- Body weight <50 kg with history of severe GI intolerance: Substantially higher drug exposure increases toxicity risk
Use with Caution
- Asthma or COPD: Cholinergic stimulation may cause bronchoconstriction
- Urinary obstruction: Cholinomimetic effects may exacerbate retention symptoms
- History of seizures: Cholinergic agents have theoretical pro-convulsant potential; seizures also occur as part of AD progression
- Concurrent NSAID use: Monitor for GI bleeding; gastroprotection recommended
- Planned surgery requiring general anaesthesia: Inform anaesthetist; rivastigmine may potentiate succinylcholine-type muscle relaxants
Post-marketing reports have documented serious adverse events — including hospitalisation and, rarely, death — resulting from medication errors with the transdermal patch. The most common error is failure to remove the old patch before applying a new one, leading to accidental overdose. Caregivers must be educated to remove the previous day’s patch before placing a new one and to apply only one patch at a time. Each used patch should be folded adhesive-side together and disposed of safely.
Patient Counselling
Purpose of Therapy
Rivastigmine is prescribed to help preserve memory, thinking, and the ability to perform daily activities in people with Alzheimer’s disease or Parkinson’s disease dementia. It works by boosting the levels of a chemical messenger in the brain called acetylcholine. It does not cure the underlying disease, but it may slow the rate of cognitive decline and maintain independence for a longer period. Caregivers play a central role in ensuring the medication is taken correctly and in reporting any new symptoms to the prescribing clinician.
How to Take
Capsules: Take with food in the morning and evening. Swallow whole with water. Patch: Apply once daily to clean, dry, hairless skin on the upper back, chest, or upper arm. Press firmly for 30 seconds. Remove the old patch before applying a new one. Rotate application sites and do not reuse the same area for 14 days. Replace the patch at the same time each day.
Sources
- Exelon (rivastigmine tartrate) Capsules and Oral Solution — FDA-approved Prescribing Information. Novartis Pharmaceuticals. Revised 2018. accessdata.fda.gov Primary source for oral rivastigmine dosing, adverse reactions, pharmacokinetics, and drug interactions.
- Exelon Patch (rivastigmine transdermal system) — FDA-approved Prescribing Information. Novartis Pharmaceuticals. Revised 2015. accessdata.fda.gov Source for transdermal patch dosing, switching from oral, application-site reaction data, and severe AD indication.
- Rivastigmine Transdermal System — DailyMed label (Amneal Pharmaceuticals, revised July 2024). dailymed.nlm.nih.gov Most recently revised generic transdermal label; confirms current dosing and safety information.
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509-2518. doi:10.1056/NEJMoa041470 Landmark EXPRESS trial establishing rivastigmine efficacy in PDD; source for PDD adverse event incidence rates.
- Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease — rivastigmine patch versus capsule (IDEAL study). Int J Geriatr Psychiatry. 2007;22(5):456-467. doi:10.1002/gps.1788 Demonstrated equivalence of 9.5 mg/24 h patch to 12 mg/day capsules with fewer GI adverse effects.
- Farlow MR, Grossberg GT, Sadowsky CH, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia (ACTION study). CNS Neurosci Ther. 2013;19(10):745-752. doi:10.1111/cns.12158 Supported FDA approval of high-dose patch for severe AD; provided safety data in advanced disease.
- Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(3):249-258. doi:10.1016/S1474-4422(15)00389-0 Phase 2 trial of rivastigmine for fall prevention in PD without dementia; supports off-label gait instability use.
- Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease — an evidence-based medicine review (MDS Evidence-Based Medicine Committee). Mov Disord. 2019;34(2):180-198. doi:10.1002/mds.27602 MDS evidence-based review classifying rivastigmine as efficacious for PDD treatment.
- National Institute for Health and Care Excellence (NICE). Dementia: assessment, management, and support for people living with dementia and their carers. NICE guideline [NG97]. 2018 (updated 2023). nice.org.uk/guidance/ng97 UK guideline recommending AChE inhibitors (including rivastigmine) as first-line for mild-to-moderate AD and PDD.
- Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther. 1998;20(4):634-647. doi:10.1016/S0149-2918(98)80127-6 Foundational pharmacology review covering dual AChE/BuChE inhibition and regional brain selectivity.
- Hossain M, Jhee SS, Shiovitz T, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer’s type. Clin Pharmacokinet. 2002;41(3):225-234. doi:10.2165/00003088-200241030-00006 Definitive bioavailability study establishing ~36–72% bioavailability depending on analytical method.
- Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37(1):9-16. doi:10.1097/WNF.0000000000000010 76-week study comparing capsule vs patch safety in PDD; provides long-term adverse event data.
- Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord. 2006;21(4):456-461. doi:10.1002/mds.20700 48-week open-label extension of the EXPRESS trial confirming sustained cognitive benefits in PDD.